Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 760 | 36.59K | 323 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --760 | --36.59K | --323 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | 158.89K | 169.04K | 57.07K | 0 | 0 | 0 | ||||
| Gross profit | -158.13K | -132.44K | -56.74K | 0 | 0 | 0 | ||||
| Operating expense | 29.20%1.39M | 47.58%1.7M | 5.22%998.42K | 172.29%4.24M | 76.25%1.06M | 250.98%1.08M | 261.67%1.15M | 188.45%948.9K | 34.15%1.56M | 149.53%602.91K |
| Selling and administrative expenses | 67.12%1.05M | 104.76%1.49M | -27.64%438.37K | 176.14%2.22M | 68.31%181.71K | 219.84%628.97K | 175.05%727.36K | 375.30%605.8K | 29.54%805.44K | 294.79%107.96K |
| -Selling and marketing expense | 51.43%154.39K | 5.45%122.89K | ---- | ---- | ---- | 54.61%101.95K | 96.67%116.54K | ---- | ---- | ---- |
| -General and administrative expense | 70.15%896.74K | 123.71%1.37M | -27.64%438.37K | 176.14%2.22M | 40.46%480.47K | 303.19%527.02K | 197.69%610.82K | 375.30%605.8K | 29.54%805.44K | 1,647.37%342.08K |
| Research and development costs | -5.19%136.35K | -23.60%136.65K | --135.75K | --429.74K | --107.07K | --143.82K | --178.85K | --0 | --0 | --0 |
| Depreciation amortization depletion | --815 | --779 | --257 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| -Depreciation and amortization | --815 | --779 | --257 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Other operating expenses | -33.60%200.78K | -69.90%74.12K | 23.59%424.05K | 110.98%1.59M | 56.35%773.83K | 175.70%302.39K | 354.29%246.27K | 70.27%343.1K | 39.46%751.42K | 66.63%494.95K |
| Operating profit | -43.90%-1.55M | -59.08%-1.83M | -11.20%-1.06M | -172.29%-4.24M | -76.25%-1.06M | -250.98%-1.08M | -261.67%-1.15M | -188.45%-948.9K | -34.15%-1.56M | -149.53%-602.91K |
| Net non-operating interest income (expenses) | -96.73%66 | -52.03%673 | 2,995.48%5.48K | 400.51%13.61K | 268.22%10.01K | 2.02K | 1.4K | 177 | 2.72K | 2.72K |
| Non-operating interest income | -96.73%66 | -52.03%673 | 2,995.48%5.48K | 400.51%13.61K | 268.22%10.01K | --2.02K | --1.4K | --177 | --2.72K | --2.72K |
| Other net income (expenses) | -3,998.33%-12.3K | 139.27%4.95K | 92.62%-8.72K | 1,663.00%328.89K | 2,063.49%459.91K | -106.87%-300 | -560.50%-12.61K | -155,310.53%-118.11K | 72.32%-21.04K | -130.01%-23.42K |
| Gain on sale of security | -411.93%-3.35K | 159.05%1.93K | 27.86%-233 | 153.72%11.3K | 166.35%15.54K | -114.98%-654 | -70.77%-3.26K | -325.00%-323 | -431.11%-21.04K | -256.01%-23.42K |
| Special income (charges) | -2,627.40%-8.95K | 132.37%3.03K | 92.80%-8.49K | --317.58K | --444.37K | --354 | ---9.35K | ---117.79K | --0 | --0 |
| -Less:Impairment of capital assets | --0 | --0 | --0 | --12.81K | ---444.37K | ---354 | --13.53K | --444K | --0 | --0 |
| -Less:Other special charges | ---- | ---- | ---- | ---330.4K | --0 | ---- | ---4.19K | ---326.21K | ---- | ---- |
| -Less:Write off | --8.95K | ---3.03K | --8.49K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Other non-operating income (expenses) | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --326.21K | ---- | ---- |
| Income before tax | -45.27%-1.56M | -57.06%-1.83M | 0.79%-1.06M | -147.38%-3.9M | 4.96%-592.69K | -255.49%-1.07M | -263.02%-1.16M | -224.23%-1.07M | -27.38%-1.58M | -281.23%-623.61K |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -45.27%-1.56M | -57.06%-1.83M | 0.79%-1.06M | -147.38%-3.9M | 4.96%-592.69K | -255.49%-1.07M | -263.02%-1.16M | -224.23%-1.07M | -27.38%-1.58M | -281.23%-623.61K |
| Net income continuous operations | -45.27%-1.56M | -57.06%-1.83M | 0.79%-1.06M | -147.38%-3.9M | 4.96%-592.69K | -255.49%-1.07M | -263.02%-1.16M | -224.23%-1.07M | -27.38%-1.58M | -281.23%-623.61K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -45.27%-1.56M | -57.06%-1.83M | 0.79%-1.06M | -147.38%-3.9M | 4.96%-592.69K | -255.49%-1.07M | -263.02%-1.16M | -224.23%-1.07M | -27.38%-1.58M | -281.23%-623.61K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -45.27%-1.56M | -57.06%-1.83M | 0.79%-1.06M | -147.38%-3.9M | 4.96%-592.69K | -255.49%-1.07M | -263.02%-1.16M | -224.23%-1.07M | -27.38%-1.58M | -281.23%-623.61K |
| Diluted earnings per share | 0.00%-0.02 | -50.00%-0.03 | 0.00%-0.02 | -133.33%-0.07 | 0.00%-0.01 | -100.00%-0.02 | -100.00%-0.02 | -100.00%-0.02 | 40.00%-0.03 | -118.63%-0.01 |
| Basic earnings per share | 0.00%-0.02 | -50.00%-0.03 | 0.00%-0.02 | -133.33%-0.07 | 0.00%-0.01 | -100.00%-0.02 | -100.00%-0.02 | -100.00%-0.02 | 40.00%-0.03 | -118.63%-0.01 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.